Glimelius B, Påhlman L
Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):305-12. doi: 10.1016/0360-3016(87)90003-4.
Between 1978 and 1984, 44 consecutive patients with anal epidermoid carcinoma were either given radiation therapy alone (cloacogenic type) or in combination with Bleomycin (squamous type). The patients with small tumors (T1-T2) were treated to 65 Gy or 60 Gy + Bleomycin directly, whereas patients with moderately advanced tumors (T3) were treated to the same radiation dose, only if no evidence of residual disease existed after 50-55 Gy (40-45 Gy + Bleomycin); if a palpable tumor still remained 3 weeks after the irradiation, surgery was performed. Patients with tumors in Stage T4 were treated to 60-65 Gy (+/- Bleomycin) followed by surgery. The outcome has so far been excellent. All but four patients, treated according to the regimen and with no initial metastases, are alive and well; two died postoperatively, one developed urinary bladder recurrence, and one liver metastases. Nineteen patients have a preserved anal function. Only one of the 9 patients also treated with an abdomino-perineal excision had viable tumor at surgery. It is concluded that patients with an anal carcinoma can be safely treated with preservation of the anus in a significant proportion of the cases, and that a combined treatment approach most likely improves survival.
1978年至1984年间,44例连续性肛管表皮样癌患者,分别接受单纯放疗(泄殖腔源型)或放疗联合博来霉素治疗(鳞状细胞型)。小肿瘤(T1-T2)患者直接接受65 Gy或60 Gy +博来霉素治疗,而中度进展期肿瘤(T3)患者,仅在50-55 Gy(40-45 Gy +博来霉素)后无残留疾病证据时,才接受相同的放疗剂量;如果放疗3周后仍可触及肿瘤,则进行手术。T4期肿瘤患者接受60-65 Gy(±博来霉素)治疗后进行手术。目前结果非常好。除4例按方案治疗且无初始转移的患者外,其余患者均存活且情况良好;2例术后死亡,1例发生膀胱复发,1例发生肝转移。19例患者保留了肛门功能。在9例同时接受腹会阴切除术治疗的患者中,只有1例在手术时有存活肿瘤。结论是,相当一部分肛管癌患者可以通过保留肛门进行安全治疗,联合治疗方法很可能提高生存率。